Copyright
©The Author(s) 2021.
World J Stem Cells. Aug 26, 2021; 13(8): 1030-1048
Published online Aug 26, 2021. doi: 10.4252/wjsc.v13.i8.1030
Published online Aug 26, 2021. doi: 10.4252/wjsc.v13.i8.1030
Ref. | Country | Species | Ischemia model | Cell source | Key outcomes |
Geng et al[84], 2019 | China | Rats | MCAO | Adipose | Improve tissue recovery, neurogenesis, angiogenesis; Reduce Inflammation |
Xin et al[93], 2013 | America | Rats | MCAO | Adipose | Improve brain recovery, angiogenesis; Reduce infarct volume, inflammation |
Chen et al[82], 2016 | Taiwan | Rats | MCAO | BM | Improve tissue recovery, neurogenesis, angiogenesis, neuronal plasticity |
Tian et al[91], 2018 | China | Mice | MCAO | BM | Inhibit inflammatory response and apoptosis |
Xin et al[92], 2017 | America | Rats | MCAO | BM | Improve tissue recovery, neurogenesis, neuronal and neurite plasticity |
Jiang et al[85], 2018 | China | Rats | MCAO | Adipose | Reduce infarct volume and inflammation |
Yang et al[94], 2018 | China | Mice | Photothrombosis | BM | Promote angiogenesis |
Zhang et al[95], 2019 | China | Mice | MCAO | BM | Promote angiogenesis |
Liu et al[87], 2019 | China | Rat | MCAO | BM | Improved brain neuron density and neurological score |
Deng et al[83], 2019 | China | Mice | MCAO | BM | Reduce infarct volume and inflammation |
Nalamolu et al[88], 2019 | America | Rats | MCAO | UC | Improve brain recovery; Reduce infarct volume |
Nalamolu et al[89], 2019 | America | Rats | MCAO | UC | Improve brain recovery; Reduce infarct volume |
Li et al[86], 2020 | China | Mice | MCAO | UC | Reduce infarct volume; Inhibit inflammatory response and apoptosis |
Zhao et al[20], 2020 | China | Rats | MCAO | BM | Reduce infarct volume and inflammation; Improve neurological deficits |
Zhao et al[21], 2020 | China | Rats | MCAO | BM | Improve motor, learning and memory abilities; Reduce inflammation |
Safakheil and Safakheil[90], 2020 | Iran | Rats | MCAO | BM | Improve functional recovery; Reduce infarct volume and inflammation |
Otero-Ortega et al[100], 2020 | Spain | Rats | Endothelin-1 | Adipose | Improve functional recovery and cells proliferation, Reduce infarct volume |
Otero-Ortega et al[103], 2017 | Spain | Rats | Endothelin-1 | Adipose | Improve functional recovery and neurogenesis, Reduce infarct volume |
Moon et al[101], 2019 | South Korea | Rats | MCAO | Cord blood | Promote angiogenesis and neurogenesis |
Doeppner et al[80], 2015 | Germany | Mice | MCAO | BM | Improve tissue recovery, neurogenesis, and angiogenesis |
Dabrowska et al[99], 2019 | Poland | Rats | Ouabain | BM | Reduce inflammation |
Haupt et al[98], 2021 | Germany | Mice | MCAO | BM | Increased neurological recovery and neurogenesis |
Xia et al[97], 2020 | China | Rats | MCAO | BM | Reduce infarct volume neurological deficits, Enhance angiogenesis |
Wang et al[102], 2020 | Germany | Mice | Stroke | BM | Immunosuppression and neuroprotection |
Kuang et al[96], 2020 | Germany | Mice | MCAO | Adipose | Reduced neuronal death and infarct size, Increased neurological recovery |
Ref. | Country | Species | Cell type | Dosage | Route | Cell | Delivery | Microglia | Microglia | Signal | Ischemic |
Source | Timing | Marker | Activation | Pathway | Model | ||||||
Cunningham et al[109], 2020 | United Kingdom | Mice | MSCs | 1.4 × 106 | Sub | BM | 1 h and 24 h | Iba1 | No effect | IL-1α | MCAO |
Narantuya et al[115], 2010 | Japan | Rats | MSCs | NA | IV | BM | NA | ED1/Iba1 | Inhibit | NA | BCAO |
Ishizaka et al[111], 2013 | Japan | Rats | MSCs | 1 × 106 | IA | NA | 1, 4 or 7 d | ED1 | Inhibit | NA | MCAO |
Yamaguchi et al[120], 2018 | Japan | Rats | MSCs | 1 × 106 | IA | Blood | 24 h | Iba1 | Inhibit | NA | MCAO |
Wang et al[119], 2014 | China | Rats | MSCs | 2 × 106 | IV | BM | 3 h | CD45/CD11b | Inhibit | NA | dMCAO |
Wei et al[19], 2012 | America | Rats | MSCs | 1 × 106 | IV | BM | 24 h | Iba1/OX-42 | Inhibit | NA | MCAO |
Nakajima et al[114], 2017 | Japan | Rats | MSCs | 1 × 106 | IV | BM | 0 or 3 h | Iba1/TNF-α/IL6/IL-1β | Inhibit | IL-10 | MCAO |
McGuckin et al[113], 2013 | France | Rats | MSCs | NA | Stereotaxis | UC | NA | ED1/Iba1 | Inhibit | CD200/STAT3 | Ouabain injection |
Li et al[112], 2018 | China | Rats | MSCs | 1 × 106 | IV | BM | 1 h | CD68/Iba1 | Inhibit | IGF-1/BDNF | dMCAO |
Lv et al[108], 2016 | China | Cells | MSCs | NA | NA | BM | NA | TNF-α/IL6/IL-1β | Inhibit | TNF-α/MSCs/GDNF | OGD |
Wang et al[102], 2020 | Germany | Mice | EVs | 2 × 106 | IV | BM | Immediately | CD45/CD11b | Inhibit | NA | MCAO |
Dabrowska et al[99], 2019 | Poland | Rats | EVs | 5 × 105 | IA | BM | 48 h | ED1 | Inhibit | NA | Ouabain injection |
Geng et al[84], 2019 | China | Rats | EVs | NA | NA | Adipose | NA | Iba1, TNF-α, IL-1β | Inhibit | miRNA-126 | MCAO |
Liu et al[87], 2019 | China | Rats | EVs | 5 × 105 | IV | BM | 2 h | Iba1 | Inhibit | NA | MCAO |
Tian et al[91], 2018 | China | Mice | EVs | NA | IV | BM | 12 h | Iba1 | Inhibit | NA | MCAO |
Sheikh et al[117], 2019 | Japan | Rats | MSCs | 3 × 106 | IV | BM | 24 h | ED1/Iba1 | Inhibit | IL-1β/HIF-1α and VEGF | MCAO |
Wang et al[118], 2013 | Japan | Rats | MSCs | 3 × 106 | IV | BM | 24 h | ED1/Iba1/IL-1β/TNF-α/iNOS, MCP-1 | Inhibit | TLR2/CD40/NF-kB | MCAO |
Yoo et al[122], 2013 | South Korea | Rats | MSCs | 5 × 105 | Stereotaxis | BM | 3 days | CD68/Iba1/MCP-1; TNF-α/iNOS/IL-1β | Inhibit | TGF-β1/MCP-1 | MCAO |
Sheikh et al[116], 2011 | Japan | Rats | MSCs | 3 × 106 | IV | BM | 24 h | Iba1/iNOS/Cox-2/IL8/MCP-1 | Inhibit | IL5 and Fractalkine | MCAO |
Feng et al[110], 2020 | China | Mice | MSCs | 1 × 106/20 g | IV | UC | 2 weeks | M1: CD16/32, Iba1; M2: CD206 | Polarization | H3 methylation | LPS |
Yang et al[121], 2020 | China | Rats | MSCs | 1 × 106 | IV | BM | 24 h before | M1: iNOS/Iba1; M2: Arg 1 | Polarization | miR-30a* | MCAO |
Jiang et al[85], 2018 | China | Rats | EVs | NA | IV | Adipose | NA | M1: TNF-α/IL-6/iNOS; M2: IL-4/CD206/IL-10 | Polarization | miR-30d-5p | MCAO |
Li et al[86], 2020 | China | Mice | EVs | NA | IV | UC | NA | M1: iNOS/CD38/ IL-6/TNF-α/CCL-2; M2: Arg 1/CD206 | Polarization | miR-26b-5p | MCAO |
Zhao et al[20], 2020 | China | Rats | EVs | 200 μL | IV | BM | 1 or 14 d | M1: CD16-32/IL-6/IL-1β; M2: CD206/ IL-10 | Polarization | miR-223-3p/ CysLT2R | MCAO |
Zhao et al[21], 2020 | China | Rats | EVs | 200 μL | IV | BM | 2 h | M1: CD86 NOS/IL-12/TNF-α; M2: CD206 /TGF-β/BDNF | Polarization | CysLT2R and ERK1/2 | MCAO |
Ref. | Country | Design | Type | Route | MSCs source | Sample size (cases) | Dose | How long | Follow-up | |
Auto or allo | MSCs | Control | (Mean) | (Mean) | (Mean) | |||||
Savitz et al[137], 2011 | America | Non-RCT | Acute | IV | BM/Auto | 10 | NA | 100 × 106 | 1-3 d | 0.5 yr |
Lee et al[138], 2010 | South Korea | RCT | Acute | IV | PIC/Auto | 16 | 36 | 50 × 106 | 1 wk | 5 yr |
Bhasin et al[151], 2011 | India | Non-RCT | Chronic | IV | BM/Auto | 4 | 5 | 50-60 × 106 | 8 wk | 24 wk |
Bhasin et al[139], 2012 | India | Non-RCT | Chronic | IV | PIC/Auto | 12 | 12 | 50-60 × 106 | 3-24 mo | 0.5 yr |
Bhasin et al[140], 2016 | India | Non-RCT | Chronic | IV | PIC/Auto | 20 | 20 | 50-60 × 106 | 3-24 mo | 0.5 yr |
Chen et al[141], 2014 | China | RCT | Chronic | Stereotactic | PB/Auto | 15 | 15 | 3-8 × 106 | 0.5-5 yr | 1 yr |
Jiang et al[149], 2013 | China | Non-RCT | NA | Catheterization | UC/Allo | 3 | NA | 20 × 106 | 11-22 d | 0.5 yr |
Laskowitz et al[14], 2018 | America | RCT | Acute | IV | UC/Allo | 10 | 10 | 3.34 × 106 | 3-9 d | 1 yr |
Levy et al[142], 2019 | America | Non-RCT | Chronic | IV | NA/Allo | 15 and 20 | NA | NA | NA | 1 yr |
Moniche et al[143], 2012 | Spain | RCT | Subacute | IA | PIC/Auto | 10 | 10 | 159 × 106 | 5-9 d | 0.5 yr |
Prasad et al[144], 2014 | India | RCT | Subacute | IV | PIC/Auto | 60 | 60 | 280.5 × 106 | 1-4 mo | 0.5 yr |
Suárez-Monteagudo et al[150], 2009 | Cuba | Non-RCT | NA | IV | BM/Auto | 3 | NA | NA | NA | 3 M |
Vahidy et al[145], 2019 | America | RCT | Acute | IV | BM/Auto | 25 | 30 | NA | 1-3 d | 2 yr |
Zhang et al[146], 2019 | China | Non-RCT | NA | Stereotactic | FSC/Allo | 9 | NA | NA | 494 d | 2 yr |
Díez-Tejedor et al[148], 2014 | Spain | RCT | Acute | IV | Adipose/Allo | 20 | 20 | NA | 0.5 mo | 2 yr |
Feng et al[147], 2014 | China | NA | Subacute | Stereotactic | UC/Allo | 50 | 50 | 100 × 106 | 0.5-1 mo | 0.25 yr |
Jaillard et al[153], 2020 | France | RCT | Subacute | IV | BM/Allo | 16 | 15 | 100-300 × 106 | 3 wk | 24 mo |
De Keyser[152], 2005 | South Korea | Non-RCT | Acute | IV | BM/Allo | 5 | 25 | 50 × 106 | 4-9 wk | 12 mo |
- Citation: Xin WQ, Wei W, Pan YL, Cui BL, Yang XY, Bähr M, Doeppner TR. Modulating poststroke inflammatory mechanisms: Novel aspects of mesenchymal stem cells, extracellular vesicles and microglia. World J Stem Cells 2021; 13(8): 1030-1048
- URL: https://www.wjgnet.com/1948-0210/full/v13/i8/1030.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v13.i8.1030